Overview
Hanne Callewaert is chief executive officer of Astrivax Therapeutics, a role she has held since July 2022. She is based in Bekkevoort. In July 2021 she founded HanXelle BV, where she is founding manager and director.
She joined Oxurion in June 2018 as global head of regulatory affairs, adding responsibility for business development, out-licensing and alliance management in September 2020, and served as chief operating officer from July 2021 until August 2022. Before that she spent nine years at GSK, beginning at GSK biologicals in March 2009 as a technical regulatory affairs scientist and moving on to roles at GSK Vaccines in clinical and global regulatory affairs and as a vaccine development lead, latterly as director and vaccine development leader until May 2018. She began her career as a patent attorney trainee at GEVERS in 2008.
Callewaert completed a master in biomedical sciences at KU Leuven, followed by a PhD in medical sciences there, and a master after master in intellectual property law at the Katholieke Universiteit Brussel. She attended College Menen.
Career history
In the news
- Dutch only: a great interview with Astrivax Therapeutics CEO Hanne Callewaert. A wide ranging discussion on vaccines, innovation and the ecosystem of drug development in general.
- Vaccins hebben de afgelopen vijftig jaar wereldwijd meer dan 150 miljoen mensenlevens gered. Toch staan ze steeds vaker ter discussie. Volgens Hanne Callewaert, CEO van vaccinproducent AstriVax, zijn vaccins het slachtoffer van hun eigen succes. Omdat veel infectieziektes dankzij vaccinatie vrijwel verdwenen zijn, vergeten we hoe gevaarlijk ze ooit waren. Daardoor zien we vandaag vooral de mogelijke risico's van vaccinatie en verliezen we de voordelen uit het oog. Bekijk Trends Talk op Trends Z of beluister als podcast via je
- Belgium has everything it takes to turn science into innovation. We have an incredibly strong lifesciences ecosystem, but we cannot take that strength for granted! If we want to build the innovations of tomorrow here, we need the courage to fund them today, when they are still early, ambitious and inherently risky. I shared some of my thoughts in this week’s Trends Talk. #pointofview #innovation #earlystage # Astrivax Therapeutics
- Bekijk – Hanne Callewaert van biotechbedrijf Astrivax: ‘Europa is efficiënter in ontwikkeling van medicijnen dan VS’Farmabedrijven kijken steeds meer naar de Verenigde Staten voor investeringen, maar de ontwikkeling van een geneesmiddel kost nog altijd minder in Europa. Dat zegt Hanne Callewaert, de CEO van het vaccinbedrijf Astrivax in Trends Talk dit weekend. Amerikanen hebben wel meer risicoappetijt dan de Europeanen, zodat biofarmabedrijven meer kapitaal kunnen ophalen in de VS. The post Bekijk – Hanne Call
- This 𝗔𝘀𝘁𝗿𝗶𝘃𝗮𝘅 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗧𝗲𝗮𝗺 will be at the 𝗪𝗼𝗿𝗹𝗱 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 Europe in Amsterdam next week, joining the global vaccine community to exchange ideas, explore collaborations, and discuss the latest advances in vaccine development. Are you attending as well? 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 to schedule a meeting with our team. We're always eager to connect with fellow innovators, potential partners, and experts working to shape the future of vaccines. 𝗦𝗲𝗲 𝘆𝗼𝘂 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺! #WVC
- Women’s Health is high on the agenda in Europe. This week I attended “From Challenges to Action: Scaling Women’s Health Innovation in Europe” at the European Parliament, organized by Eva Kopacz, Vice President of the European Parliament, European Innovation Council and SMEs Executive Agency (EISMEA). Scientists, entrepreneurs, innovators, physicians, investors and policymakers around the table. Different perspectives, but one very clear ask: 📢 Make it actionable. Over the last years, we have spent enough time identifying the
- A week ago, Friday night ... Good music. Good friends. Local festival. And then… one badly twisted ankle. My immediate thought: “I’m flying to the US in 36 hours. This cannot be happening.” Well, it was. Sunday morning, I boarded the plane, and spent the past week navigating the US and all my meetings on two crutches and more wheelchairs than I care to count. What made it possible? People. Airport assistance in Brussels, Munich, Boston and New York. The Belgian delegation in Boston carrying my luggage, backpack, coffee and food and
- Our CEO, Hanne Callewaert, is joining the Belgian mission to Boston next week, together with FIT - Flanders Investment & Trade, bringing together innovators, investors, researchers, and industry leaders from both sides of the Atlantic. Boston is one of the world's leading biotech hubs, and we look forward to exchanging ideas, building new connections, and exploring opportunities to accelerate the development of 𝗟𝗮𝘂𝗻𝗰𝗵-𝗶𝗧 𝗛𝗣𝗩. Our goal is simple but ambitious: to intervene earlier in the HPV patient journey and
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.